Genetically Modified Dendritic Cells for Therapeutic Immunity

• Kikuchi Toshiaki

  Department of Respiratory Oncology and Molecular Medicine, Institute of Development, Aging and Cancer, Tohoku University

Abstract

Dendritic cells are professional antigen presenting cells, which show an extraordinary capacity to initiate primary immune responses by stimulating T cells. This established function of dendritic cells has attracted much attention in efforts to develop useful vaccines for the treatment of cancer and infectious diseases. Designing effective strategies to generate clinical dendritic cell-based vaccine protocols remains a challenging field of research. The successful realization of immunotherapy utilizing dendritic cells will depend on modifications of these protocols to optimize the natural stimulatory properties of dendritic cells, such as genetic modification of dendritic cells. This review focuses on dendritic cell gene modifications for enhancing the multiple effector functions of dendritic cells, including viral and non-viral gene transfer into dendritic cells, and a variety of transferred genes, such as those encoding antigens, co-stimulatory molecules, cytokines, and chemokines.

Journal

• The Tohoku Journal of Experimental Medicine

  The Tohoku Journal of Experimental Medicine 208 (1), 1-8, 2006

  Tohoku University Medical Press

Keywords

• dendritic cell
• cellular vaccine
• genetic modification
• cancer
• infectious diseases

Details

• CRID: 1390282679215655552
• NII Article ID: 130004459463
• NII Article ID: 10017087851
• NII Book ID: AA00863920
• DOI: 10.1620/tjem.208.1
• ISSN: 13493329
• ISSN: 00408727
• Web Site: http://www.jstage.jst.go.jp/article/tjem/208/1/208_1_1/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2006248410
• Text Lang: en
• Data Source:
  • JaLC
  • Crossref
  • CiNii Articles
• Abstract License Flag: Disallowed